 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Lithostat |
| AHFS/Drugs.com | Consumer Drug Information |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.008.104 |
| Chemical and physical data | |
| Formula | C2H5NO2 |
| Molar mass | 75.067 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Acetohydroxamic acid (also known as AHA or by the trade name Lithostat) is a drug that is a potent and irreversible enzyme inhibitor of the urease enzyme in various bacteria and plants; it is usually used for urinary tract infections. The molecule is similar to urea but is not hydrolyzable by urease;[1] it thus disrupts the bacteria's metabolism through competitive inhibition.
Orphan drug
In 1983 the US Food and Drug Administration approved acetohydroxamic acid (AHA) as an orphan drug for "prevention of so-called struvite stones" under the newly enacted Orphan Drug Act of 1983.[2] AHA cannot be patented because it is a standard chemical compound.[2]
See also
References
- ↑ Fishbein WN, Carbone PP (June 1965). "Urease Catalysis. Ii. Inhibition of the Enzyme by Hydroxyurea, Hydroxylamine, and Acetohydroxamic Acid". The Journal of Biological Chemistry. 240: 2407–14. doi:10.1016/S0021-9258(18)97338-2. PMID 14304845.
- 1 2 Marwick C (July 1983). "New drugs selectively inhibit kidney stone formation". JAMA. 250 (3): 321–2. doi:10.1001/jama.1983.03340030003001. PMID 6854890.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.